Status:
COMPLETED
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Polycystic Kidney, Autosomal Dominant
Chronic Kidney Diseases
Eligibility:
All Genders
Phase:
NA
Brief Summary
The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct. Autosomal dominant polycy...
Detailed Description
The aim is to measure the difference in renal function, including kidney tubular function, blood pressure and vasoactive hormones in patients with Autosomal dominant polycystic kidney disease (ADPKD) ...
Eligibility Criteria
Inclusion
- ADPKD patients: -age \>18 years, diagnosis with ADPKD, informed consent, contraception for fertile women
- Patients with chronic kidney disease: age \>18 years, diagnosis with chronic kidney disease other then ADPKD, informed consent, contraception for fertile women
- Healthy volunteers: age \>18 years, healthy, informed consent, contraception for fertile women
Exclusion
- ADPKD patients: Renal transplantation, operation in the kidney, Diabetes mellitus, neoplastic conditions, pregnancy, breastfeeding, unwillingness to participate, intolerance towards urine dilution or urine concentration test, alcohol or medical abuse, BP \>170/110 despite regulation, unacceptable side effects to background medication (antihypertensive medicine) during the trial.
- Patients with chronic kidney disease: Renal transplantation, operation in the kidney, Diabetes mellitus, medullary cystic kidney disease, lithium nephropathy, neoplastic conditions, pregnancy, nursing, unwillingness to participate, intolerance towards urine dilution or urine concentration test, alcohol or medical abuse, BP \>170/110 despite regulation, unacceptable side effects to background medication (antihypertensive medicine) during the trial.
- Healthy volunteers: Arterial hypertension, significant clinical signs of heart, lungs, liver, kidneys, endocrine, brain or neoplastic disorders, alcohol or drug abuse, medical treatment, smoking, pregnancy or breastfeeding, smoking, clinically significant abnormal findings in blood, urine tests or electrocardiogram, blood donation within the last month before the examination date in the first trial sequence, intolerance to or unacceptable side effects of urine concentration and urine dilution test
Key Trial Info
Start Date :
September 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2020
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT04363554
Start Date
September 25 2017
End Date
April 20 2020
Last Update
April 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Research, Regional Hospital Holstebro
Holstebro, Denmark, 7500